Intercell AG

EANS-Adhoc: Intercell announces Q2 and H1 2011 financial results and provides an update on execution of strategic plan

  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
6-month report


» IXIARO®/JESPECT® sales growth up by 85% in H1 2011 
» Net loss reduced by 80% in Q2 and by 44% in H1 2011
» USD 6.0m milestone payment received from Merck & Co., Inc. for S. aureus 
  interim data

Vienna (Austria), August 16, 2011 - Today, the biotech-vaccine company Intercell
AG (VSE: ICLL) announced its financial results for Q2 and H1 2011 and provided
an update on execution of strategic plan.

Financial Results

» Year-on-year revenue growth of 31.3% in Q2 2011 driven by strong 
  IXIARO®/JESPECT® sales revenues 
» Restructuring progressing successfully - cost reduction by 57.7% in R&D 
  and 21.9% in S,G&A in H1 2011
» Net loss reduction by 80.7% to EUR 1.6m in Q2 2011 and by 44.2% to 
  EUR 12.9m in H1 2011
» Cash position of EUR 79.6m at quarter-end - significant reduction of 
» Unchanged net loss expectation of EUR 30-40m for full year 2011

Key Financial Figures

EUR in thousands     3 months ended          6 months ended     Year ended
                   June 30,   June 30,    June 30,   June 30,      Dec 31,
                       2011       2010        2011       2010         2010
Revenues              12,686     9,659      18,377     14,414       34,215
Net profit/(loss)    (1,608)    (8,346)    (12,866)   (23,048)    (255,182)
Net operating 
cash flow            (5,452)   (11,026)    (28,905)   (26,494)     (65,120)
Cash and marketable
end of period        79,649    127,802      79,649    127,802       86,182


In H1 2011, the IXIARO®/JESPECT® sales were up 85% compared to H1 2010 resulting
in the best quarterly sales since launch of the product. This was made possible
through a strong uptake in the military sector and strong growth in key travel
markets such as the U.S. and the UK. Hence Intercell is on track to meet its
expectation of full-year 2011 growth rate of at least 60-70%.
Together with its distribution partner Novartis, Intercell will continue to
focus resources to further increase penetration in the key markets, the military
sector, and expand into new territories. The approval for Singapore is expected
in the next months, and the first application for approval in South America has
also been submitted.

Enrollment for the Phase III clinical study for the IXIARO® pediatric label
extension is completed. The pediatric approval is expected by the end of 2012 or
beginning of 2013. 

The pivotal Phase II/III trial in children living in India has been fully
enrolled and partner Biological E. Ltd. is moving towards submission for
licensure in India, with a planned launch in 2012.

Following an "Out of Specification" result in a follow-up test for potency of
IXIARO® lot JEV09L37 after a period of 11 months, Novartis and Intercell
initiated a batch-specific, voluntary recall in Canada (March), Europe (May) and
Australia (May), in close coordination with the relevant authorities. Vaccinee
safety is of primary importance to Intercell, and re-vaccination was initiated
for individuals who had received vaccine from the respective lot.
In addition, Intercell is performing a comprehensive investigation and root
cause analysis in order to reduce the risk for further potential recalls,
regulatory actions or batch-specific measures in the future. These activities as
well as other relevant measures and clinical implications are overseen and
governed by the EMA (European Medicines Agency) under a procedure according to
Article 20 of the Commission Regulation (EC) 726/2004. Novartis and Intercell
are working closely with the authorities to execute against the regulatory

Update on Staphylococcus aureus (V710): Intercell receives milestone payment
from Merck & Co., Inc.

Following a detailed analysis of the data from the Phase II/III clinical trial
evaluating V710, an investigational vaccine for the prevention of Staphylococcus
aureus (S. aureus) infections, the external Data Monitoring Committee (DMC)
unanimously recommended the termination of the study. On June 8, 2011, Merck &
Co., Inc. (Merck) and Intercell announced the termination of the trial.

However, as the trial did meet the pre-specified criteria for non-futility,
Intercell received the related USD 6.0m milestone payment from Merck.
Furthermore, Intercell and Merck are currently evaluating potential future
approaches in the field of S. aureus under the existing licensing agreement.

Focus on core R&D programs
» Pandemic Influenza Vaccine Enhancement Patch (VEP) - Pursuing 
  confirmatory mode of action trial with GSK antigen: The enrollment for 
  the confirmatory Phase I trial is ongoing and a first safety analysis has 
  been completed. Final data are expected by mid-2012. 

» Pneumococcus vaccine: As part of Intercell's pipeline prioritization, the 
  development of a Pneumococcus vaccine candidate has been put on hold. 

» Hepatitis C: Intercell and Romark joined forces in combining therapies 
  against Hepatitis C. Romark is still awaiting regulatory clearance for 
  study initiation of a combination Phase II trial which is expected to 
  start in H2 2011. The trial is fully funded by Romark.


» French Prix Galien 2011 awarded to IXIARO® in the category "Medicines 
  available solely in international vaccination centers"

The full report can be downloaded at

Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222

end of announcement                               euro adhoc 

issuer:      Intercell AG
             Campus Vienna Biocenter  3
             A-1030 Wien 
phone:       +43 1 20620-0
FAX:         +43 1 20620-800
sector:      Biotechnology
ISIN:        AT0000612601
indexes:     ATX Prime, ATX
stockmarkets: official market: Wien 
language:   English

Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: